Skip to main content
SpringerLink
Log in

The LRRK2 G2019S mutation as the cause of Parkinson’s disease in Ashkenazi Jews

  • Movement Disorders - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Mutations in the leucine rich repeat kinase 2 gene (LRRK2) are recognized as the most common cause of genetic Parkinsonism to date. The G2019S mutation has been implicated as an important determinant of Parkinson’s disease (PD) in both Ashkenazi Jewish and North African Arab populations with carrier frequency of 29.7% among familial and 6% in sporadic Ashkenazi Jewish PD cases. PD patients with the G2019S mutation display similar clinical characteristics to patients with sporadic PD. While the function of the LRRK2 protein has yet to be fully determined, its distribution coincides with brain areas most affected by PD. The G2019S mutation is believed to be responsible for up-regulation of LRRK2 kinase activity, which may ultimately play a role in neuronal loss. The utility of LRRK2 G2019S screening in family members of Ashkenazi PD patients is discussed. LRRK2 G2019S mutation carriers without PD may be an ideal population for the study of possible neuroprotective strategies as they become available, and for furthering the understanding of the pathogenesis and long-term clinical outcomes of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aasly JO, Toft M, Fernandez-Mata I et al (2005) Clinical features of LRRK2 associated Parkinson’s disease in central Norway. Ann Neurol 57:762–765

    Article  CAS  PubMed  Google Scholar 

  • Adams RJ, Van Netten H, Schulzer M, Mak E et al (2005) PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 128:2777–2785

    Article  PubMed  Google Scholar 

  • Bar-Shira A, Hutter C, Giladi N et al (2009) Ashkenazi Parkinson’s disease patients with the LRRK2 G2019S mutation share a common founder dating from the 2nd to 5th centuries. Neurogenetics (ahead of print)

  • Behar DM, Garrigan D, Kaplan ME, Mobasher Z et al (2004) Contrasting patterns of Y-chromosome variation in Ashkenazi Jewish and host non-Jewish European populations. Hum Genet 114:354–365

    Article  CAS  PubMed  Google Scholar 

  • Bialecka M, Hui S, Klodowska-Duda G, Opala G et al (2005) Analysis of LRRK2 G2019S mutation in Parkinson’s disease. Neurosci Lett 390(1):1–3

    Article  CAS  PubMed  Google Scholar 

  • Bonifati V (2007) LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson’s disease. Neurochem Res 32:1700–1708

    Article  CAS  PubMed  Google Scholar 

  • Bosgraaf L, Van Haastert PJM (2003) Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 1643:5–10

    Article  CAS  PubMed  Google Scholar 

  • Bras JM, Guerreiro RJ, Ribeiro MH, Januario C et al (2005) G2019S dardarin substitution is a common cause of Parkinson’s disease in a Portuguese cohort. Mov Disord 20(12):1653–1655

    Article  PubMed  Google Scholar 

  • Brice A (2005) Genetics of Parkinson’s disease: LRRK2 on the rise. Brain 128:2760–2762

    Article  PubMed  Google Scholar 

  • Carmine Belin A, Westerlund M, Sydow O, Lundströmer K et al (2006) Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Mov Disord 10:1731–1734

    Article  Google Scholar 

  • Change N, Mercier G, Lucotte G (2007) Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African and Sepharadi Jew subjects. Genet Test 12:1–8

    Google Scholar 

  • Chen-Plotkin AS, Yuan W, Anderson BS, McCarty C (2008) Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 70:521–527

    Article  CAS  PubMed  Google Scholar 

  • Cho JW, Kim SY, Park SS, Kim HJ et al (2009) The G2019S LRRK2 mutation is rare in Korean patients with Parkinson’s disease. Can J Neurol Sci 34(1):53–55

    Google Scholar 

  • Clark LN, Wang Y, Karlins E, Saito L et al (2006) Frequency of LRRK2 mutations in early and late onset Parkinson disease. Neurology 67:1786–1791

    Article  CAS  PubMed  Google Scholar 

  • Colombo R (2000) Age estimate of the N370S mutation causing Gaucher disease in Ashkenazi Jews and European populations: a reappraisal of haplotype data. Am J Hum Gent 66:692–697

    Article  CAS  Google Scholar 

  • De Rosa A, Criscuolo C, Mancini P, De Martino M et al (2009) Genetic screening for LRRK2 gene G2019S mutation in Parkinson’s disease patients from Southern Italy. Parkinsonism Relat Disord 15(3):242–244

    Article  PubMed  Google Scholar 

  • Deng H, Le W, Guo Y, Hunter CB (2005) Genetic and clinical identification of Parkinson’s disease patients with LRRK2 G2019S mutation. Ann Neurol 57(6):933–934

    Article  CAS  PubMed  Google Scholar 

  • Deng H, Le W, Guo Y, Hunter CB et al (2006) Genetic analysis of LRRK2 mutations in patients with Parkinson’s disease. J Neurol Sci 251:102–106

    Article  CAS  PubMed  Google Scholar 

  • Deng J, Lewis PA, Greggio E, Sluch E et al (2008) Structure of the ROC domain from the Parkinson’s disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci USA 105(5):1499–1504

    Article  CAS  PubMed  Google Scholar 

  • Djaldetti R, Hassin-Baer S, Farrer MJ, Vilariño–Güell C et al (2008) Clinical characteristics of Parkinson’s disease among Jewish Ethnic groups in Israel. J Neural Transm 115(9):1279–1284

    Article  CAS  PubMed  Google Scholar 

  • Dupré N, Rivière JB, Myers RH, Provencher P et al (2007) LRRK2 is not a significant cause of Parkinson’s disease in French-Canadians. Can J Neurol Sci 34(3):333–335

    PubMed  Google Scholar 

  • Farrer M, Stone J, Mata IF, Lincoln S et al (2005) LRRK2 mutations in Parkinson’s disease. Neurology 65:738–740

    Article  CAS  PubMed  Google Scholar 

  • Ferreira JJ, Guedes LC, Rosa MM, Coelho M et al (2007) High prevalence of LRRK2 mutations in familial and sporadic Parkinson’s disease in Portugal. Mov Disord 22(8):1194–1201

    Article  PubMed  Google Scholar 

  • Floris G, Cannas A, Solla P, Murro MR et al (2008) Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: Importance of G2019S and R1441C mutations in sporadic Parkinson’s disease patients. Parkinsonism Relat Disord (ahead of print)

  • Funalot B, Nichols WC, Pérez-Tur J, Mercier G, Lucotte G (2006) Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson’s disease. Genet Test 10(4):290–293

    Article  CAS  PubMed  Google Scholar 

  • Gaig C, Ezquerra M, Marti MJ, Munoz E (2006) LRRK2 mutations in Spanish patients with Parkinson disease. Arch Neurol 63:377–382

    Article  PubMed  Google Scholar 

  • Gaig C, Ezquerra M, Marti MJ, Valldeoriola F (2008) Screening for the LRRK2 G2019S mutation and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 270(1–2):94–98

    Article  CAS  PubMed  Google Scholar 

  • Gandhi PN, Chen SG, Wilson-Delfosse AL (2009) Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson’s disease. J Neurosci Res 87:1283–1295

    Article  CAS  PubMed  Google Scholar 

  • Gan-Or Z, Giladi N, Rozovski U et al (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70:2277–2283

    Article  CAS  PubMed  Google Scholar 

  • Gan-Or Z, Bar-Shira A, Mirelman A, Gurevich T et al (2009) LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics (ahead of print)

  • Gao L, Gómez-Garre P, Díaz-Corrales FJ, Carrillo F et al (2009) Prevalence and clinical features of LRRK2 mutations in patients with Parkinson’s disease in southern Spain. Eur J Neurol (ahead of print)

  • Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S et al (2005) A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet 365:415–416

    CAS  PubMed  Google Scholar 

  • Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF et al (2005) The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor. J Med Genet 42:e65

    Article  CAS  PubMed  Google Scholar 

  • Goldwurm S, Zini M, Di Fonzo A, De Gaspari D et al (2006) LRRK2 G2019S mutation and Parkinson’s disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord 16:410–419

    Article  Google Scholar 

  • Goldwurm S, Zini M, Mariani L, Tesei S et al (2007) Evaluation of LRRK2 G2019S penetrance. Neurology 68:1141–1143

    Article  CAS  PubMed  Google Scholar 

  • Gorostidi A, Ruiz-Martínez J, de Munain AL, Alzualde A, Massó JF (2009) LRRK2 G2019S and R1441G mutations associated with Parkinson’s disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 10(2):157–159

    Article  CAS  PubMed  Google Scholar 

  • Gosal D, Ross OA, Wiley J, Brent Irvine J et al (2005) Clinical traits of LRRK2 associated Parkinson’s disease in Ireland: a link between familial and idiopathic PD. Parkinsonism Relat Disord 11:349–352

    Article  PubMed  Google Scholar 

  • Greggio E, Cookson MR (2009) Leucine rich repeat kinase 2 mutations and Parkinson’s disease: three questions. ASN Neuro 14(1):13–24

    Article  Google Scholar 

  • Greggio E, Zambrano I, Kaganovich A, Beilina A et al (2008) The Parkinson disease associated Leucine rich repeat kinase 2 (LRRK) is a dimmer that undergoes intramolecular autophosphorylation. J Biol Chem 283(24):16906–16914

    Article  CAS  PubMed  Google Scholar 

  • Hardy J, Huabian C, Cookson MR, Gwinn-Hardy K et al (2006) Genetics of Parkinson’s disease and Parkinsonism. Ann Neurol 60:389–398

    Article  CAS  PubMed  Google Scholar 

  • Hassin-Baer S, Laitman Y, Azizi E, Molchadski I (2009) The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. J Neurol 256:483–487

    Article  CAS  PubMed  Google Scholar 

  • Healy DG, Falchi M, O’Sullivan SS, Borifati V (2008) Phenotype, genotype and worldwide genetic penetrance of LRRK2 associated Parkinson’s disease: a case control study. Lancet Neurol 7:583–590

    Article  CAS  PubMed  Google Scholar 

  • Huang Y, Halliday GM, Vandebona H, Mellick GD et al (2007) Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson’s disease. Mov Disord 22(7):982–989

    Article  PubMed  Google Scholar 

  • Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L et al (2008) LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case control genetic study. Lancet Neurol 7:591–594

    Article  CAS  PubMed  Google Scholar 

  • Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV et al (2007) A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson’s disease in Russia. Eur J Neurol 14(4):413–417

    Article  CAS  PubMed  Google Scholar 

  • Infante J, Rodríguez E, Combarros O, Mateo I et al (2006) LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson’s disease. Neurosci Lett 395(3):224–226

    Article  CAS  PubMed  Google Scholar 

  • Isaias IU, Benti R, Goldwurm S, Zini M et al (2006) Striatal dopamine transporter binding in Parkinson’s disease associated with LRRK2 Gly2019Ser mutation. Mov Disord 21(8):1144–1147

    Article  PubMed  Google Scholar 

  • Ishihara L, Gibson RA, Warre L, Amour R et al (2006a) Screening for LRRK2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson’s disease families. Mov Disord 22:55–61

    Article  Google Scholar 

  • Ishihara L, Warren L, Gibson R, Amouri R et al (2006b) Clinical features of Parkinson disease patients with homozygous Leucin-rich repeat kinase 2 G2019S mutations. Arch Neurol 63:1250–1254

    Article  PubMed  Google Scholar 

  • Johnson J, Paisán-Ruíz C, Lopez G, Crews C et al (2007) Comprehensive screening of a North American Parkinson’s disease cohort for LRRK2 mutation. Neurodegener Dis 4(5):386–391

    Article  CAS  PubMed  Google Scholar 

  • Kachergus J, Mata IF, Hulihan M, Taylor JP et al (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant Parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76:672–680

    Article  CAS  PubMed  Google Scholar 

  • Kalinderi K, Fidani L, Bostantjopoulou S, Katsarou Z, Kotsis A (2007) The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson’s disease. Eur J Neurol 14(10):1088–1090

    Article  CAS  PubMed  Google Scholar 

  • Kay DM, Zabetian CP, Factor SA, Nutt JG et al (2006a) Parkinson’s disease and LRRK2: frequency of a common mutation in US movement disorder clinics. Mov Disord 21(4):519–523

    Article  PubMed  Google Scholar 

  • Kay DM, Bird TD, Zabetian CP, Factor SA et al (2006b) Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson’s disease. Genet Test 3:221–227

    Article  Google Scholar 

  • Khan NL, Jain S, Lynch JM, Pavese N et al (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128:2786–2796

    Article  PubMed  Google Scholar 

  • Klein C, Schlossmacher MG (2007) Parkinson disease, 10 years after its genetic revolution. Neurology 69:2093–2104

    Article  PubMed  Google Scholar 

  • Klein C, Lohmann-Hedrich K, Rogavena E, Schlossmacher MG, Lang AE (2007) Deciphering the role of heterozygous mutations in genes associated with Parkinsonism. Lancet Neurol 6:652–662

    Article  CAS  PubMed  Google Scholar 

  • Latourelle J, Sun M, Lew MF, Suchowersky O et al (2008) The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson’s disease: the GenePD study. BMC Med; 5; 6; 32

    Google Scholar 

  • Lesage S, Ibanez P, Lohmann E, Pollak P et al (2005a) G2019S LRRK2 mutation in French and North African families with Parkinson’s disease. Ann Neurol 58:784–787

    Article  CAS  PubMed  Google Scholar 

  • Lesage S, Leutenegger AL, Ibanez P, Janin S et al (2005b) LRRK2 haplotype analysis in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 77:330–332

    Article  CAS  PubMed  Google Scholar 

  • Lesage S, Durr A, Tazir M, Lohmann E et al (2006) LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med 354:422–423

    Article  CAS  PubMed  Google Scholar 

  • Lesage S, Belarbi S, Troiano A, Condroyer C et al (2008) Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease? Neurology 71:1550–1552

    Article  CAS  PubMed  Google Scholar 

  • Lin CH, Tzen KY, Yu CY, Tai CH et al (2008) LRRK2 mutation in familial Parkinson’s disease in a Taiwanese population: clinical, PET, and functional studies. J Biomed Sci 15(5):661–667

    Article  PubMed  Google Scholar 

  • Lu YW, Tan EK (2008) Molecular biology changes associated with LRRK2 mutations in Parkinson’s disease. J Neurosci Res 86:1895–1901

    Article  CAS  PubMed  Google Scholar 

  • MacLeod D, Dowman J, Hammond R, Leete T et al (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52(4):587–593

    Article  CAS  PubMed  Google Scholar 

  • Marongiu R, Ghezzi D, Ialongo T, Soleti F et al (2006) Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson’s disease. Mov Disord 21(8):1232–1235

    Article  PubMed  Google Scholar 

  • Mata IF, Kachergus JM, Taylor JP, Lincoln S et al (2005) LRRK2 pathogenic substitutions in Parkinson’s disease. Neurogenetics 6:171–177

    Article  CAS  PubMed  Google Scholar 

  • Mata IF, Ross OA, Kachergus J, Huerta C et al (2006) LRRK2 mutations are a common cause of Parkinson’s disease in Spain. Eur J Neurol 13:391–394

    Article  CAS  PubMed  Google Scholar 

  • Mata IF, Cosentino C, Marca V, Torres L et al (2009) LRRK2 mutations in patients with Parkinson’s disease from Peru and Uruguay. Parkinsonism Relat Disord 15(5):370–373

    Article  PubMed  Google Scholar 

  • Melrose H (2008) Update on functional biology of LRRK2. Future Neurol 3(6):669–681

    Article  CAS  PubMed  Google Scholar 

  • Miklossy J, Arai T, Guo JP, Klegeris A et al (2006) LRRK2 expression in normal and pathological human brain and in human cell lines. J Neuropathol Exp Neurol 65:953–963

    Article  CAS  PubMed  Google Scholar 

  • Möller JC, Rissling I, Mylius V, Höft C et al (2008) The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson’s disease. Eur J Neurol 15(7):743–745

    Article  PubMed  Google Scholar 

  • Munhoz RP, Wakutani Y, Marras C, Helio TA et al (2008) The G2019S LRRK2 mutation in Brazilian patients with Parkinson’s disease: phenotype in monozygotic twins. Mov Disord 23:290–294

    Article  PubMed  Google Scholar 

  • Nandhagopal R, Mak E, Schulzer M, McKenzie J et al (2008) Progression of dopaminergic dysfunction in LRRK2 kindred. A multitracer PET study. Neurology 71:1790–1795

    Article  CAS  PubMed  Google Scholar 

  • Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C et al (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet 365:410–412

    CAS  PubMed  Google Scholar 

  • Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S et al (2007) The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease. Neurology 69:1595–1602

    Article  CAS  PubMed  Google Scholar 

  • Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E et al (2006) LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med 354:424–425

    Article  CAS  PubMed  Google Scholar 

  • Paisan-Ruiz C, Jain S, Evans EW, Gilks WP et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44(4):595–600

    Article  CAS  PubMed  Google Scholar 

  • Papapetropoulos S, Adi N, Shehadeh L, Bishopric N et al (2008) Is the G2019S LRRK2 mutation common in all southern European populations? J Clin Neurosci 15(9):1027–1030

    Article  CAS  PubMed  Google Scholar 

  • Papaptropoulos S, Singer C, Ross OA, Toft M et al (2006) Clinical heterogeneity of the LRRK2 G2019S mutation. Arch Neurol 63:1242–1246

    Article  Google Scholar 

  • Patra B, Parsian A, Racette BA et al (2009) LRRK2 gene G2019S mutation and SNP’s (haplotypes) in subtypes of Parkinson’s disease. Parkinsonism Relat Disord 15:175–180

    Article  PubMed  Google Scholar 

  • Pavese N, Brooks DJ (2008) Imaging neurodegeneration in Parkinson’s disease. Biochim Biophys Acta (ahead of print)

  • Pchelina SN, Yakimovski AF, Ivanova ON, Emelianov AK et al (2006) G2019S LRRK2 mutation in familial and sporadic Parkinson’s disease in Russia. Mov Disord 21(12):2234–2236

    Article  PubMed  Google Scholar 

  • Pchelina SN, Yakimovski AF, Emelyanov AK, Ivanova ON et al (2008) Screening for LRRK2 mutations in patients with Parkinson’s disease in Russia: identification of a novel LRRK2 variant. Eur J Neurol 15:692–696

    Article  CAS  PubMed  Google Scholar 

  • Perez-Pastene C, Cobb SA, Díaz-Grez F, Hulihan MM et al (2007) LRRK2 mutations in South America: a study of Chilean Parkinson’s disease. Neurosci Lett 422(3):193–197

    Article  CAS  PubMed  Google Scholar 

  • Perry G, Zhu X, Babar AK, Siedlak SL et al (2008) Leucine-rich repeat kinase 2 colocalizes with α-synuclein in Parkinson’s disease, but not Tau-containing deposits in Tauopathies. Neurodegener Dis 5:222–224

    Article  CAS  PubMed  Google Scholar 

  • Pimentel MM, Moura KC, Abdalla CB, Pereira JS et al (2008) A study of LRRK2 mutations and Parkinson’s disease in Brazil. Neurosci Lett 433(1):17–21

    Article  CAS  PubMed  Google Scholar 

  • Punia S, Behari M, Govindappa ST, Swaminath PV et al (2006) Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson’s disease patients. Neurosci Lett 409:83–88

    Article  CAS  PubMed  Google Scholar 

  • Rajput A, Dickson DW, Robinson CA, Ross OA et al (2006) Parkinsonism, LRRK2 G2019S, and tau neuropathology. Neurology 67:1506–1508

    Article  CAS  PubMed  Google Scholar 

  • Ross OA, Toft M, Whittle AJ et al (2006) LRRK2 and Lewy body disease. Ann Neurol 59:388–393

    Article  CAS  PubMed  Google Scholar 

  • Santpere G, Ferrer I (2009) LRRK2 and neurodegeneration. Acta Neuropathol 117:227–246

    Article  CAS  PubMed  Google Scholar 

  • Saunders-Pullman R, Lipton RB, Senthil G, Katz M et al (2006) Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia. Neurosci Lett 402:92–96

    Article  CAS  PubMed  Google Scholar 

  • Shojaee S, Sina F, Farboodi N, Fazlali Z et al (2009) A clinic-based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson’s disease patients. Mov Disord 24(7):1023–1027

    Article  PubMed  Google Scholar 

  • Silveita-Moriyama L, Guedes LC, Kingsbury A, Ayling H et al (2008) Hyposmia in G2019S LRRK2-related Parkinsonism. Neurology 71:1021–1026

    Article  Google Scholar 

  • Spanaki C, Latsoudis H, Plaitakis A (2006) LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 67(8):1518–1519

    Article  PubMed  Google Scholar 

  • Squillaro T, Cambi F, Ciacci G, Rossi S et al (2007) Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson’s disease. J Hum Genet 52(3):201–204

    Article  CAS  PubMed  Google Scholar 

  • Tan EK, Shen H, Tan LC, Farrer M et al (2005) The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson’s disease patients. Neurosci Lett 384(3):327–329

    Article  CAS  PubMed  Google Scholar 

  • Tanner CM, Ottman R, Goldman SM, Ellen J et al (1999) Parkinson disease in twins. FAMA 281:341–346

    Article  CAS  Google Scholar 

  • Tomiyama H, Li Y, Funayama M, Hasegawa K (2006) Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson’s disease patients from 18 countries. Mov Disord 8:1102–1108

    Article  Google Scholar 

  • Tompkins MM, Hill WD (1997) Contribution of somal Lewy bodies to neuronal death. Brain Res 24:24–29

    Article  Google Scholar 

  • Warren L, Gibson R, Ishihara L, Elango R et al (2008) A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson’s disease. Parkinsonism Relat Disord 14:77–80

    Article  CAS  PubMed  Google Scholar 

  • West AB, Moore DJ, Biskup S, Bugayenko A et al (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. PNAS 102(46):16842–16847

    Article  CAS  PubMed  Google Scholar 

  • Williams-Gray CH, Goris A, Foltynie T, Brown J et al (2006) Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson’s disease cohort. J Neurol Neurosurg Psychiatry 77(5):665–667

    Article  CAS  PubMed  Google Scholar 

  • Zabetian C, Samii A, Mosely AD, Roberts AW et al (2005) A clinical based study of the LRRK2 gene in Parkinson’s disease yields new mutations. Neurology 65:741–744

    Article  CAS  PubMed  Google Scholar 

  • Zabetian C, Hutter CM, Yearout D, Lopez AN et al (2006a) LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79:752–758

    Article  CAS  PubMed  Google Scholar 

  • Zabetian CP, Morino H, Ujike H, Yamamoto M et al (2006b) Identification and haplotype analysis of LRRK2 G2019S in Japanese with Parkinson disease. Neurology 67:697–699

    Google Scholar 

  • Zhu X, Babar A, Siedlak SL, Yang Q et al (2006) LRRK2 in Parkinson’s disease and dementia with Lewy bodies. Mol Neurodegener 1:17

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Sourasky Medical Center, Tel-Aviv, Israel

    Avner Thaler, Elissa Ash & Nir Giladi

  2. Genetic Institute, Sourasky Medical Center, Tel-Aviv, Israel

    Ziv Gan-Or & Avi Orr-Urtreger

  3. Sackler School of Medicine, Tel-Aviv, Israel

    Avner Thaler, Ziv Gan-Or, Avi Orr-Urtreger & Nir Giladi

Authors
  1. Avner Thaler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elissa Ash
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ziv Gan-Or
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Avi Orr-Urtreger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nir Giladi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Avner Thaler or Nir Giladi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thaler, A., Ash, E., Gan-Or, Z. et al. The LRRK2 G2019S mutation as the cause of Parkinson’s disease in Ashkenazi Jews. J Neural Transm 116, 1473–1482 (2009). https://doi.org/10.1007/s00702-009-0303-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-009-0303-0

Keywords

Search

Navigation